Author: Charlotte PRIMARD

Home - Articles posted by Charlotte PRIMARD

Custom formulations adapted to poorly water-soluble active ingredients

Anyone working on the development of active ingredients knows the difficulties encountered during this lengthy process, right from the R&D phases. Adjuvatis is here to help you overcome these challenges leading to the pharmaceutical product. Find out in 5 minutes the services of API formulation provided by Adjuvatis, and how we can help you to[...]
Read More

Versatile formulation of active ingredients, adapted to poorly water-soluble or rapidly metabolised drugs, allowing their solubilisation, protection and targeted delivery

Interested in Adjuvatis’ drug formulation technology but want to learn more? Meet us at the Forum de la Recherche en Cancérologie organized by the Canceropole Rhone-Alpes CLARA, in April. Charlotte Primard, our CEO, will pitch Versatile formulation of active ingredients, adapted to poorly water-soluble or rapidly metabolised drugs, allowing their solubilisation, protection and targeted delivery.[...]
Read More

Improving antibiotic delivery in Staphylococcus aureus biofilms

Da Costa D, et al., Surface charge modulation of rifampicin-loaded PLA nanoparticles to improve antibiotic delivery in Staphylococcus aureus biofilms J Nanobiotechnology, 2021 After the golden age of antibiotic discovery, bacterial infections still represent a major challenge for public health worldwide. The biofilm mode of growth is mostly responsible for chronic infections that current therapeutics[...]
Read More

Development of an antibacterial nanocomposite hydrogel for human dental pulp engineering

Bekhouche M, et al., Development of an antibacterial nanocomposite hydrogel for human dental pulp engineering J. Mater. Chem. B, 2020 Hydrogel-based regenerative endodontic procedures (REPs) are considered to be very promising therapeutic strategies to reconstruct the dental pulp (DP) tissue in devitalized human teeth. However, the success of the regeneration process is limited by residual[...]
Read More

Adjuvatis’ young talents

Congratulations to Dr David Da Costa for his PhD defense, in December 2020 !! Development of combinatorial therapy based on anti-biofilm agents and poly-lactic acid particles for the delivery of antibiotics against bacterial biofilms Under the direction of Bernard Verrier (LBTI) and Charlotte Primard (Adjuvatis)
Read More

Adjuvatis’ young talents

Targeting Steatosis with Autophagy-Inducing Particles. A poster presented by Stavroula Zagkou, PhD Candidate from DRIVE-Autophagy ETN Dec 2020 – Drug Discovery Day Lille Sept 2020 – Nanomedicine and Drug Delivery Symposium (NanoDDS) Aug 2020 – Keystone Autophagy
Read More

2020: Adjuvatis remained by your side

2020 has been full of regular meetings, we look forward to seeing you in 2021!   Dec 2020 – BioFit The leading European partnering event for early-stage deals and investment rounds in the field of Life Sciences     Oct 2020 – Semaine Collaborative Lyon Biopole     May 2020 – COVID-19 Virtual Partnering Accelerate[...]
Read More

Solubilization of an hydrophobic API for anti-cancer treatment

Poor water solubility is one of the most significant barrier limiting drug development. Indeed, more than 40% of compounds identified through combinatorial screening programs display poor aqueous solubility, which is associated with poor bioavailability, suboptimal dosing, etc. Adjuvatis uses a safe-by-design technology that allows formulation of APIs with little or no solubility. Adjuvatis develops biocompatible[...]
Read More

A recombinant vaccine based on i-Particles is protective against H1N1 influenza infection

Tetrahymena cell
Recombinant Haemagglutinin Derived From the Ciliated Protozoan Tetrahymena thermophila Is Protective Against Influenza Infection Context Cilian AG (Germany), affiliated as well as Adjuvatis, to the European consortium ADITEC, lead the production of a recombinant influenza haemagglutinin, using the ciliated protozoan Tetrahymena thermophila. Combined with NOD2 i-Particles, this H1N1 recombinant vaccine is protective against influenza protection.[...]
Read More

FASTCURE: a consortium of experts to respond to the epidemic COVID-19 coronavirus outbreak

FASTCURE is a consortium of experts for screening, identification and formulation of chemical compounds to combat SARS-CoV-2. Drug repurposing can be a key strategy to fight against pathogens, especially when it comes as a rapid response to an emerging pathogen such as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) identified in Wuhan, China in January[...]
Read More